Resonance Specialties Reports ₹2,153.35 Lakh Revenue in Q2 FY26; Net Profit Up 50.14%

Resonance Specialties Limited announced strong financial results for Q2 FY2025-26, reflecting robust growth in revenue and profitability. The performance highlights operational efficiency and sustained demand in domestic and international markets.

Key Financial Highlights

• Revenue from Operations: ₹2,153.35 lakh, up 19.20% YoY from ₹1,806.45 lakh
• Net Profit: ₹165.70 lakh, up 50.14% YoY from ₹110.36 lakh
• Half-Year Revenue: ₹4,338.97 lakh, up 20.69% YoY
• Half-Year Net Profit: ₹328.74 lakh, up 48.21% YoY
• EPS (H1 FY26): ₹2.85 vs ₹1.92 in H1 FY25

The company’s strong earnings growth underscores its ability to maintain profitability while scaling operations.

Segment-Wise Revenue Distribution

Resonance Specialties operates primarily in chemical manufacturing, with exports driving growth:

• Domestic Sales: ₹2,005.94 lakh (46.86% of total revenue)
• Export Sales: ₹2,274.83 lakh (53.14% of total revenue)
• Total: ₹4,280.77 lakh

The export contribution of over 53% highlights the company’s competitive positioning in global markets.

Operational Efficiency and Market Position

The company’s focus on high-value chemical products and strong international demand has supported margin expansion. Improved EPS and consistent revenue growth reflect its resilience amid market fluctuations.

At 2:12 PM IST on November 3, 2025, Resonance Specialties share price stood at ₹99.10, up by ₹1.10. The stock showed a positive movement during the trading session.

Read More: Pfizer Deal Sparks Pharma Rally.

Conclusion

Resonance Specialties delivered a strong Q2 FY26 performance with double-digit revenue growth and a sharp rise in net profit. With exports contributing significantly and operational efficiency improving, the company is well-positioned for sustained growth in the chemical manufacturing sector.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.